Document text
Principal Investigator: KUNLE ODUNSI
Organization: UNIVERSITY OF CHICAGO
Fiscal Year: 2023
Award: $226,986
Funding agency: National Cancer Institute
ABSTRACT
The main purpose of the Human Immunologic Monitoring and Current Good Manufacturing Practice (HIMcGMP) Facility is to provide support to investigators at the University of Chicago Medicine Comprehensive
Cancer Center (UCCCC) who conduct immunotherapy clinical trials through preparing vaccines and other
novel immunotherapies for patient administration, and by evaluating various immunologic endpoints from
patient samples. The HIM Subcore was initiated in 1999 as a Developing Core and has been under continuous
direction by Thomas Gajewski, MD, PhD, since that time. In 2002, the HIM Core Facility became a full CCSG
Core. The cGMP Subcore was initiated as a UCCCC Developing Core in 2001 and has been under continuous
direction by Amittha Wickrema, PhD, since its inception. In 2011, the HIM Facility formally merged with the
cGMP Facility, which streamlined the interface between the two components, including shared technical staff.
With the increasing role of immunotherapy in the portfolio of cancer therapeutics, the activities of the HIMcGMP Facilty are vital for the scientific investigation of novel agen and have been expanding rapidly. In
addition to providing standard assays to measure immunologic endpoints and to monitor biologic effects of
other pharmacologic agents using lymphocytes as a surrogate tissue, the Facilty has integrated new
technologies to facilitate the study of novel biomarkers in patients. For example, UCCCC investigators first
described the T cell-inflamed/non-inflamed tumor microenvironment gene expression profile that has been
explored as a predictive biomarker for response to checkpoint blockade therapy. Understanding the
mechanism by which this spontaneous anti-tumor T cell response develops in some patients, and the
mechanism by which immune exclusion occurs in the remaining patients, is highlighting mechanisms of
resistance and new therapeutic targets. The HIM-cGMP Facility has integrated new technologies that are
facilitating identification of these mechanisms. The Facility recently purchased a Nanostring nCounter
instrument, which enables gene expression profiling from formalin-fixed paraffin-embedded (FFPE) tissue, as
well as an RNAscope system, for visualizing in situ expression of specific mRNAs. In addition, new protocols
for banking stool for microbiota sequencing, blood for germline DNA analysis, and serum for specialized
biochemical assays have been developed. Thus, in addition to standard immunologic assays, the HIM-cGMP
Facility is facilitating the analysis of multidimensional correlations between mutational patterns in the tumor,
germline genetic polymorphisms, and the composition of intestinal micriobiota, all with respect to
immunotherapy clinical outcome.
Terms: <Antineoplastic Vaccine><Assay><Bio-Informatics><Bioassay><Biochemical><Bioinformatics><Biologic Assays><Biologic Monitoring><Biological><Biological Assay><Biological Monitoring><Blood><Blood Reticuloendothelial System><Blood Serum><Body Tissues><Budgets><CCSG><Cancer Center Support Grant><Cancer Patient><Cancer Vaccines><Cancers><Cell Body><Cell Therapy><Cells><Chicago><Clinical><Clinical Cancer Center><Clinical Trials><Comprehensive Cancer Center><Consultations><Core Facility><Cyclic GMP><DNA><DNA analysis><Deoxyribonucleic Acid><Development><Dimensions><Doctor of Philosophy><Drugs><Elements><Evaluation><Exclusion><Expression Signature><Faculty><Feces><Formalin><Funding><Gene Expression Monitoring><Gene Expression Pattern Analysis><Gene Expression Profile><Gene Expression Profiling><Genetic Alteration><Genetic Change><Genetic Polymorphism><Genetic defect><Genomic Data Commons><Genomics><Good Manufacturing Process><Good manufacturing practice><Grant><Guanosine Cyclic Monophosphate><Heart><Histologic><Histologically><Host-Tumor Interaction><Hour><Human><Human Activities><Immune><Immune Markers><Immune Monitoring><Immune mediated therapy><Immune response><Immunes><Immunity><Immunochemical Immunologic><Immunologic><Immunologic Markers><Immunologic Monitoring><Immunological><Immunological Monitoring><Immunological response><Immunologically><Immunologically Directed Therapy><Immunologics><Immunology procedure><Immunomonitoring><Immunotherapeutic agent><Immunotherapy><In Situ><Industry><Infrastructure><Intervention><Intervention Strategies><Intestinal><Intestines><Investigation><Investigators><Lab Findings><Laboratories><Laboratory Finding><Lymphatic cell><Lymphocyte><Lymphocytic><Malignant Neoplasms><Malignant Tumor><Measures><Medication><Medicine><Messenger RNA><Mission><Modern Man><Molecular><Molecular Analysis><Mutation><Neoplasm Vaccines><Outcome><Output><Paraffin Embedding><Patients><Pattern><Ph.D.><PhD><Pharmaceutic Preparations><Pharmaceutical Agent><Pharmaceutical Preparations><Pharmaceuticals><Pharmacologic Substance><Pharmacological Substance><Philanthropic Fund><Preparation><Principal Investigator><Prognostic Marker><Protocol><Protocols documentation><Regulation><Research Personnel><Research Resources><Researchers><Resources><Role><Sampling><Serum><Services><Site><Source><Specific qualifier value><Specified><System><T cell response><T-cell inflamed><Therapeutic><Time><Tissue Embedding><Tissues><Transcript Expression Analyses><Transcript Expression Analysis><Translating><Tumor Vaccines><Universities><Vaccines><Visualization><Work><analyze DNA><analyze gene expression><anti-cancer immunotherapy><anti-tumor vaccine><anticancer immunotherapy><antitumor vaccine><biologic><biomonitoring><bowel><cGMP><cancer clinical trial><cancer immunotherapy><cancer microenvironment><cell mediated therapies><cell-based therapeutic><cell-based therapy><cellular therapeutic><cellular therapy><check point blockade><checkpoint blockade><clinical applicability><clinical application><consultation><developmental><drug/agent><gene expression analysis><gene expression assay><gene expression pattern><gene expression signature><genome mutation><host neoplasm interaction><host response><immune check point blockade><immune checkpoint blockade><immune drugs><immune system response><immune therapeutic approach><immune therapeutic interventions><immune therapeutic regimens><immune therapeutic strategy><immune therapy><immune-based biomarkers><immune-based cancer therapies><immune-based therapeutics><immune-based therapies><immune-based treatments><immuno therapy><immunologic assay><immunologic assay/test><immunologic therapeutics><immunological biomarkers><immunological markers><immunoresponse><immunotherapeutics><immunotherapy agent><immunotherapy clinical trials><immunotherapy for cancer><immunotherapy of cancer><improved><instrument><interventional strategy><lymph cell><mRNA><malignancy><manufacture><manufacturing environment><marine><marine environment><member><microbial consortia><microbial flora><microbiome sequencing><microbiota><microflora><multispecies consortia><nano-string><nanostring><neoplasm/cancer><new drug target><new druggable target><new marker><new pharmacotherapy target><new technology><new therapeutic target><new therapy target><novel><novel biomarker><novel drug target><novel druggable target><novel marker><novel pharmacotherapy target><novel technologies><novel therapeutic target><novel therapy target><oncology clinical trial><peripheral blood><pharmaceutical><pharmacodynamic biomarker><pharmacodynamic marker><pharmacologic><polymorphism><predictive biomarkers><predictive marker><predictive molecular biomarker><preparations><prognostic biomarker><resistance mechanism><resistant mechanism><response biomarker><response markers><scale up><social role><stool><stool sample><stool specimen><transcriptional profile><transcriptional profiling><transcriptional signature><tumor><tumor microenvironment><vaccine for cancer>